Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Investigation|April 21, 2015
Immunosurveillance and therapy of multiple myeloma are CD226 dependentCamille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, et al.
Blood|July 11, 2018
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myelomaCamille Guillerey, Heidi Harjunpää, Nadège Carrié, et al.
Blood|February 24, 2022
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myelomaSahar Kassem, Béré K Diallo, Nizar El-Murr, et al.
Cancer Discovery|January 21, 2016
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer ImmunotherapyStephen J Blake, Kimberley Stannard, Jing Liu, et al.
JCI Insight|June 14, 2019
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma modelCamille Guillerey, Kyohei Nakamura, Andrea C Pichler, et al.
Immunity|June 24, 2026
The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapyArantxa Agesta, Chloé Ferrand, Anne-Louise Le Dorze, et al.
Blood|April 21, 2024
RAS/RAF landscape in monoclonal plasma cell conditionsAnais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, et al.
Immunity|July 1, 2023
TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiationAndrea C Pichler, Nadège Carrié, Marine Cuisinier, et al.
Immunity|October 14, 2020
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer ImmunotherapyMarianne Weulersse, Assia Asrir, Andrea C Pichler, et al.
Blood|October 30, 2024
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myelomaJan Eckmann, Tanja Fauti, Marlene Biehl, et al.
Pageof 5